IP Library › Granted Patent US 10,662,226
Granted Patent B2
US 10,662,226 · App. 15/794,776 · Granted May 26, 2020

Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers

Inventors: James S. Nowick (Irvine, CA); Adam G. Kreutzer (Irvine, CA); Ryan K. Spencer (Ripon, CA); Patrick J. Salveson (Irvine, CA)
Assignee: The Regents of the University of Caiifomia
C07K14/001C07K1/22C07K14/4711C07K16/18C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,662,226
App. No.
15/794,776
Granted
May 26, 2020
Kind
B2
Abstract

Synthetic Aβ peptides, oligomers, their methods of synthesis, and their applications are provided. The Aβ peptides can form stable, soluble oligomers important for the advancement of knowledge, detection, and treatment of Alzheimer's disease. Antibodies specific to oligomeric Aβ and their methods of synthesis are also described.

Claims (48)

1. A compound comprising:

a synthetic beta-amyloid peptide wherein the synthetic beta-amyloid peptide is a peptide selected from a group consisting of:

a peptide comprising Seq. ID. No. 3 or a substantially similar sequence;

a peptide comprising Seq. ID. No. 4 or a substantially similar sequence;

a peptide consisting of a first and a second strand, wherein the first strand comprises Seq. ID No. 5 or a substantially similar sequence, and the second strand comprises Seq. ID No. 6 or a substantially similar sequence;

wherein the first and second strand are covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the first strand to the C-terminus of the second strand; and

wherein the first and second strand are also covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the second strand to the C-terminus of the first strand; and

a peptide consisting of a first and a second strand, wherein the first strand comprises Seq. ID No. 7 or a substantially similar sequence, and the second strand comprises Seq. ID No. 8 or a substantially similar sequence;

wherein the first and second strand are covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the first strand to the C-terminus of the second strand; and

wherein the first and second strand are also covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the second strand to the C-terminus of the first strand;

wherein any of the substantially similar sequences consists of an addition, a removal, or a substitution of up to three amino acids yet maintains each cysteine amino acid of the peptide in its identified position.

2. The compound of claim 1 , wherein any of the substantially similar sequences consists of an addition, a removal, or a substitution of up to two amino acids but still maintains each cysteine amino acid of the peptide in its identified position.

3. The compound of claim 1 , wherein any of the substantially similar sequences consists of an addition, a removal, or a substitution of one amino acids but still maintains each cysteine amino acid of the peptide in its identified position.

4. The compound of claim 1 , wherein any of the sequences is an identical sequence that does not have an addition, a removal, or a substitution of an amino acid.

5. The compound of claim 1 , further comprising at least two more synthetic beta-amyloid peptides, wherein three synthetic beta-amyloid peptides are covalently linked by cysteine disulfide bridges to form a trimer.

6. The compound of claim 5 , wherein the trimer consists of a first, a second, and a third synthetic beta-amyloid peptide;

wherein each peptide consists of a first and a second strand;

wherein the first strand comprises Seq. ID No. 5 or a substantially similar sequence, and the second strand comprises Seq. ID No. 6 or a substantially similar sequence;

wherein the first and second strand are covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the first strand to the C-terminus of the second strand, and

wherein the first and second strand are also covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the second strand to the C-terminus of the first strand;

wherein the cysteine in amino acid position two of the first strand of the first peptide forms a disulfide linkage with the cysteine in amino acid position six of the first strand of the second peptide;

wherein the cysteine in amino acid position two of the first strand of the second peptide forms a disulfide linkage with the cysteine in amino acid position six of the first strand of the third peptide;

wherein the cysteine in amino acid position two of the first strand of the third peptide forms a disulfide linkage with the cysteine in amino acid position six of the first strand of the first peptide; and

wherein any of the substantially similar sequences consists of an addition, a removal, or a substitution of up to three amino acids yet maintains each cysteine amino acid of the peptide in its identified position.

7. The compound of claim 5 , wherein the trimer consists of a first, a second, and a third synthetic beta-amyloid peptide;

wherein each consists of a first and a second strand;

wherein the first strand comprises Seq. ID No. 7 or a substantially similar sequence, and the second strand comprises Seq. ID No. 8 or a substantially similar sequence;

wherein the first and second strand are covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the first strand to the C-terminus of the second strand, and

wherein the first and second strand are also covalently linked by the delta-amino group of the side chain of the N-terminal ornithine of the second strand to the C-terminus of the first strand;

wherein the cysteine in amino acid position two of the second strand of the first peptide forms a disulfide linkage with the cysteine in amino acid position six of the second strand of the second peptide;

wherein the cysteine in amino acid position two of the second strand of the second peptide forms a disulfide linkage with the cysteine in amino acid position six of the second strand of the third peptide;

wherein the cysteine in amino acid position two of the second strand of the third peptide forms a disulfide linkage with the cysteine in amino acid position six of the second strand of the first peptide; and

wherein any of the substantially similar sequences consists of an addition, a removal, or a substitution of up to three amino acids yet maintains each cysteine amino acid of the peptide in its identified position.

8. The compound of claim 5 , wherein at least one synthetic beta-amyloid peptide incorporates an ornithine in the amino acid position that corresponds to methionine35 of a naturally occurring beta-amyloid peptide.

9. The compound of claim 5 , wherein at least one central amino acid is N-methylated.

10. The compound of claim 5 , wherein the synthetic beta-amyloid peptide has at least one amino acid mutation that corresponds to familial Alzheimer's disease.

11. The compound of claim 5 , wherein the trimer consists of a first, a second, and a third synthetic beta-amyloid peptide;

wherein each peptide comprises Seq. ID No. 3 or a substantially similar sequence;

wherein the cysteine in amino acid position two of the first peptide forms a disulfide linkage with the cysteine in amino acid position six of the second peptide;

wherein the cysteine in amino acid position two of the second peptide forms a disulfide linkage with the cysteine in amino acid position six of the third peptide;

wherein the cysteine in amino acid position two of the third peptide forms a disulfide linkage with the cysteine in amino acid position six of the first peptide; and

wherein the substantially similar sequence consists of an addition, a removal, or a substitution of up to three amino acids yet maintains each cysteine amino acid of the peptide in its identified position.

12. The compound of claim 5 , wherein the trimer consists of a first, a second, and a third synthetic beta-amyloid peptide;

wherein each peptide comprises Seq. ID No. 4 or a substantially similar sequence;

wherein the cysteine in amino acid position fifteen of the first peptide forms a disulfide linkage with the cysteine in amino acid position nineteen of the second peptide;

wherein the cysteine in amino acid position fifteen of the second peptide forms a disulfide linkage with the cysteine in amino acid position nineteen of the third peptide;

wherein the cysteine in amino acid position fifteen of the third peptide forms a disulfide linkage with the cysteine in amino acid position nineteen of the first peptide; and

wherein the substantially similar sequence consists of an addition, a removal, or a substitution of up to three amino acids yet maintains each cysteine amino acid of the peptide in its identified position.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2018
From: NOWICK, JAMES S.; KREUTZER, ADAM G.; SPENCER, RYAN K.; SALVESON, PATRICK J.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 044644/0594 →
Continuity (2)
Provisional Application 62414326 · Oct 28, 2016
Related Publication 20180118790A1 · May 3, 2018
Cited By (3)
US 12,227,567 US 12,281,166 US 12,497,458